Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AOC2 | O75106 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1393075 | 0.86 | USP2 (0.35) | GRM1ALDH1A1USP2LMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL6802948 | 0.84 | USP2 (0.34) | GRM1ALDH1A1USP2LMNACYP1A2 | |
| SCHEMBL17299153 | 0.83 | GRM1 (0.43) | GRM1ALDH1A1USP2LMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL27041637 | 0.81 | GRM1 (0.41) | GRM1ALDH1A1USP2LMNACYP1A2 | |
| SCHEMBL31116092 | 0.79 | ALDH1A1 (0.33) | GRM1ALDH1A1 | |
| SCHEMBL17732059 | 0.78 | USP2 (0.35) | ALDH1A1USP2LMNACYP1A2TSHR | |
| SCHEMBL21542371 | 0.77 | ALDH1A1 (0.32) | GRM1ALDH1A1 | |
| SCHEMBL10210793 | 0.77 | ALDH1A1 (0.35) | GRM1ALDH1A1 | |
| SCHEMBL16700084 | 0.77 | ALDH1A1 (0.32) | GRM1ALDH1A1 | |
| SCHEMBL13163057 | 0.75 | CHRM1 (0.33) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324803-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3983412-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-114206866-A | Prostaglandin E2Receptor 4 antagonists and uses thereof | 泰昂治疗公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2020251957-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020251957-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20200039921-A1 | ANTIFIBRINOLYTIC COMPOUNDS | CHIBBER BAKSHY A (US) | 2020-02-06 | — | — | US | disclosed |
| US-10202331-B2 | Antifibrinolytic compounds | THROMBOLYTICS LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170334834-A1 | ANTIFIBRINOLYTIC COMPOUNDS | THROMBOLYTICS, LLC (US) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324803-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | PTGER4, PTGER1, PTGER2 | GRM1 642/4885ALDH1A1 1203/4885USP2 2860/4885 |
| US-10202331-B2 | Antifibrinolytic compounds | F2, FGB, SERPINC1 | GRM1 4324/4885ALDH1A1 3804/4885USP2 3309/4885 |
| US-20170334834-A1 | ANTIFIBRINOLYTIC COMPOUNDS | F2, SERPINC1, F12 | GRM1 4711/4885ALDH1A1 930/4885USP2 3345/4885 |
| US-20200039921-A1 | ANTIFIBRINOLYTIC COMPOUNDS | F2, SERPINC1, F12 | GRM1 4711/4885ALDH1A1 930/4885USP2 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.